Fed. Circ. Lets Stand Vanda Ruling That Led To USPTO Memo
The full Federal Circuit said Tuesday it won't reconsider a panel's decision to uphold a patent for Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, which had spurred a U.S. Patent and Trademark...To view the full article, register now.
Already a subscriber? Click here to view full article